From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

Iron chelation therapy (ICT) has become a mainstay in heavily transfused hematological patients, with the aim to reduce iron overload (IOL) and prevent organ damage. This therapeutic approach is already widely used in thalassemic patients and in low-risk Myelodysplastic Syndrome (MDS) patients. More...

Full description

Bibliographic Details
Main Authors: Giuseppe A. Palumbo, Sara Galimberti, Wilma Barcellini, Daniela Cilloni, Nicola Di Renzo, Elena Maria Elli, Carlo Finelli, Luca Maurillo, Alessandra Ricco, Pellegrino Musto, Rodolfo Russo, Roberto Latagliata
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
iron chelation therapy (ICT)
deferasirox
myelodysplastic syndromes (MDS)
myelofibrosis (MF)
radical oxygen species (ROS)
iron toxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.752192/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.752192/full

Similar Items